Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa.

Misra M, McGrane J, Miller KK, Goldstein MA, Ebrahimi S, Weigel T, Klibanski A

Bone10 Jun 2009Cited by 64 (Europe PMC)

PMID19523548PMCIDPMC3590307DOI10.1016/j.bone.2009.06.002PepBankPUB-19523548

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In girls with anorexia nervosa, PINP percent change was higher with rhIGF-1 than without intervention.
In plain wordsIn girls with anorexia nervosa, PINP increased more with rhIGF-1 than without treatment.
Peptide
IGF-1 (mecasermin)
Outcome
IncreasePINP percent change
Study
n = 20
Comparator
No intervention
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30-40 mcg/k twice daily · 7-9 daysAs given in this study (human).
Measurements
P value for PINP percent change comparison
0.02 p value
rhIGF-1 group versus no intervention group
Source sentences
Summary
Percent change in PINP was significantly higher (p=0.02) and percent change in CTX was significantly lower (p=0.006) in girls who received rhIGF-1 compared to those who did not receive any intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
RhIGF-1 was administered at a dose of 30-40 mcg/k twice daily to 10 consecutive girls with AN 12-18 years old for 7-9 days.
Summary · context
Ten age-matched girls with AN were followed without rhIGF-1 for a similar period.
Report a problemFND-1952354804
02HumanNon-randomized trialEfficacy outcome
In girls with anorexia nervosa, CTX percent change was lower with rhIGF-1 than without intervention.
In plain wordsIn girls with anorexia nervosa, the percent change in the bone resorption marker CTX was lower with rhIGF-1 than with no intervention.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseCTX percent change
Study
n = 20
Comparator
No intervention
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30-40 mcg/k twice daily · 7-9 daysAs given in this study (human).
Measurements
P value for CTX percent change comparison
0.006 p value
rhIGF-1 group versus no intervention group
Source sentences
Summary
Percent change in PINP was significantly higher (p=0.02) and percent change in CTX was significantly lower (p=0.006) in girls who received rhIGF-1 compared to those who did not receive any intervention.
2 context sentences(design, population, supporting numbers)
Summary · context
RhIGF-1 was administered at a dose of 30-40 mcg/k twice daily to 10 consecutive girls with AN 12-18 years old for 7-9 days.
Summary · context
Ten age-matched girls with AN were followed without rhIGF-1 for a similar period.
Report a problemFND-1952354805
03HumanNon-randomized trialEfficacy outcome
In girls with anorexia nervosa, rhIGF-1 increased IGF‑1 from day-1 to day-4/5 and day-8/9.
In plain wordsIn girls with anorexia nervosa, rhIGF-1 raised IGF‑1 levels from baseline at both later measurements.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseIGF-1 levels
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30-40 mcg/k twice daily · 7-9 daysAs given in this study (human).
Measurements
P value for IGF-1 increase
< 0.0001 p value
rhIGF-1 group, day-1 versus day-4/5
P value for IGF-1 increase
< 0.0001 p value
rhIGF-1 group, day-1 versus day-8/9
Source sentences
Summary
RhIGF-1 administration caused an increase in IGF-1 from day-1 to day-4/5 (p<0.0001) and day-1 to day-8/9 (p<0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
RhIGF-1 was administered at a dose of 30-40 mcg/k twice daily to 10 consecutive girls with AN 12-18 years old for 7-9 days.
Summary · context
Ten age-matched girls with AN were followed without rhIGF-1 for a similar period.
Report a problemFND-1952354801
04HumanNon-randomized trialEfficacy outcome
In girls with anorexia nervosa, rhIGF-1 increased PINP over both baseline intervals and between the later measurements.
In plain wordsIn girls with anorexia nervosa, rhIGF-1 raised the bone formation marker PINP over time.
Peptide
IGF-1 (mecasermin)
Outcome
IncreasePINP levels
Study
n = 10
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30-40 mcg/k twice daily · 7-9 daysAs given in this study (human).
Measurements
P value for PINP increase
0.004 p value
rhIGF-1 group, day-1 versus day-4/5
P value for PINP increase
0.004 p value
rhIGF-1 group, day-1 versus day-8/9
P value for PINP increase
0.048 p value
rhIGF-1 group, day-4/5 versus day-8/9
Source sentences
Summary
Simultaneously, PINP increased from day-1 to day-4/5 (p=0.004) and day-1 to day-8/9 (p=0.004), with a smaller increase from day-4/5 to day-8/9 (p=0.048).
2 context sentences(design, population, supporting numbers)
Summary · context
RhIGF-1 was administered at a dose of 30-40 mcg/k twice daily to 10 consecutive girls with AN 12-18 years old for 7-9 days.
Summary · context
Ten age-matched girls with AN were followed without rhIGF-1 for a similar period.
Report a problemFND-1952354802
05HumanNon-randomized trialEfficacy outcome
In girls with anorexia nervosa, CTX did not change with rhIGF-1.
In plain wordsIn girls with anorexia nervosa, rhIGF-1 did not change the bone resorption marker CTX.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeCTX levels
Study
n = 10
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30-40 mcg/k twice daily · 7-9 daysAs given in this study (human).
Source sentences
Summary
CTX levels did not change with rhIGF-1 administration.
2 context sentences(design, population, supporting numbers)
Summary · context
RhIGF-1 was administered at a dose of 30-40 mcg/k twice daily to 10 consecutive girls with AN 12-18 years old for 7-9 days.
Summary · context
Ten age-matched girls with AN were followed without rhIGF-1 for a similar period.
Report a problemFND-1952354803
06HumanNon-randomized trialSafety outcome
In girls with anorexia nervosa, rhIGF-1 was well tolerated without hypoglycemia.
In plain wordsIn girls with anorexia nervosa, rhIGF-1 was well tolerated without low blood sugar.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableHypoglycemia
Study
n = 10
Outcome group
Adverse events · Metabolic and weight
Studied dose
30-40 mcg/k twice daily · 7-9 daysAs given in this study (human).
Source sentences
Summary
RhIGF-1 was well tolerated without hypoglycemia.
2 context sentences(design, population, supporting numbers)
Summary · context
RhIGF-1 was administered at a dose of 30-40 mcg/k twice daily to 10 consecutive girls with AN 12-18 years old for 7-9 days.
Summary · context
Ten age-matched girls with AN were followed without rhIGF-1 for a similar period.
Report a problemFND-1952354806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1/2Results postedNCT00516386

Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents

Massachusetts General Hospitaln = 16Mar 2007 to Dec 2008

Anorexia Nervosa

Trial page ClinicalTrials.govUpdated 18 Nov 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.